NCT01720563View on ClinicalTrials.gov

A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Cancer-related Fatigue
Interventions
DRUG

Astragalus polysaccharides 500 mg

PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT

DRUG

Placebo

500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT

PROCEDURE

Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks

Trial Locations (1)

333

Chang Gung Memorial Hospital, Taoyuan District

Sponsors
All Listed Sponsors
lead

PhytoHealth Corporation

INDUSTRY